Intra-Cellular (ITCI) Therapies announced positive results from Study 304 evaluating the efficacy and safety of lumateperone 42 mg for the prevention of relapse in adult patients with schizophrenia. On the primary endpoint, time to relapse during the double-blind treatment phase was significantly longer in patients receiving lumateperone compared to those receiving placebo. There were 18 relapses in the lumateperone group versus 44 relapses in the placebo group. Treatment with lumateperone was associated with a 63% reduction in risk of relapse versus placebo.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- Intra-Cellular price target raised to $89 from $81 at JPMorgan
- Biotech Alert: Searches spiking for these stocks today
- Intra-Cellular price target raised to $135 from $130 at Cantor Fitzgerald
- Intra-Cellular price target raised to $119 from $113 at Canaccord
- Intra-Cellular Therapies Reports Strong Q3 Growth